We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.
- Authors
Rana P. Singh; Gagan Deep; Marie-José Blouin; Michael N. Pollak; Rajesh Agarwal
- Abstract
Chemoprevention is an upcoming approach to control cancer including prostate cancer (PCa). Here, we studied the efficacy and associated mechanisms of a chemopreventive agent silibinin against ectopically growing and established advanced human prostate carcinoma PC-3 tumor xenografts in athymic nude mice. Dietary silibinin (0.5%, w/w) did not show any adverse health effect in mice. In first protocol, silibinin started 1 week prior to xenograft implantation and continued for 60 additional days, whereas in the second protocol, silibinin treatment was started after 25 days of established tumors for 4, 8 and 16 days. Silibinin inhibited tumor growth rate in both protocols showing up to 35% (Pâ=â0.010) and 18â56% (Pâ=â0.002 to PâPâ=â0.014) decrease in tumor weight per mouse, respectively. In first protocol, silibinin decreased (PâPâin vivo antitumor efficacy of silibinin against PC-3 human PCa in both intervention protocols accompanied with its anti-proliferative, pro-apoptotic and anti-angiogenic activities. At molecular level, silibinin increased IGFBP-3, Cip1/p21, Kip1/p27 levels and ERK1/2 activation and decreased Bcl-2, survivin and VEGF levels in tumors.
- Subjects
PROSTATE cancer; CANCER research; XENOGRAFTS; HEALTH risk assessment
- Publication
Carcinogenesis, 2007, Vol 28, Issue 12, p2567
- ISSN
0143-3334
- Publication type
Article
- DOI
10.1093/carcin/bgm218